Contepo
FDA refuses to review Nabriva’s injectable antibiotic for urinary tract infections
May 1, 2019Research and Development, Sales and Marketing Contepo, Nabriva, pharma, urinary tract infections
Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
